Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Open accessThe DOI matches its Crossref record; 410 of the 410 references it cites were found in a registry or an index.
Abstract
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is thought that the majority of ICCs are derived from BECs [210], but mouse and human hepatocytes also represent potential sources for ICCs [212, 213].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies suggest that cholangiocarcinoma and other biliary tract malignancies are frequently associated with overactivation of the Notch and Hedgehog signaling pathways[61].”
From Liver regeneration after partial hepatectomy: Triggers and mechanisms (2025) · cites this paper as [61]
Experimental — accuracy not yet measuredIn the citing paper
“Intrahepatic cholangiocarcinoma (ICC) is a biliary tree neoplasia that arises in noncirrhotic and cirrhotic livers and has a rising incidence [210, 211].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766 · cited 1×
“Patients diagnosed with iCCA in liver-predominant disease might be considered for liver-directed therapies 345,346 .”
BackgroundEpithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · cited 1×
“EMT is a cell plasticity-promoting phenomenon initially reported to occur during embryogenesis, but that also takes place in cancer, enabling epithelial cancer cells to acquire mesenchymal features with invasive properties that lead to metastatic colonization 174 .”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“In a cohort of 86 patients with MMR-deficient tumours, including four patients with CCA, immune checkpoint blockade with the anti-PDL1 monoclonal antibody pembrolizumab resulted in a complete response in one of the patients with CCA and stabilization of disease in the other three 232 .”
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 2×
“…of T cell-infiltrated TMEs, characterized by infiltration of CD8 + T cells, chemo-kines and molecules responsible for T cell priming and immune infiltration, is associated with higher response to immune checkpoint blockade, whereas non-T cell-infiltrated TMEs have poorer responses 214,215 .”
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · cited 1×
“Regarding genomic alterations, CCA falls midway in the mutational spectrum of cancers 111 , with an approximately equal content of genomic alterations in iCCA (median 39 non-synonymous mutations per tumour) and eCCA (median 35 non-synonymous mutations per tumour) 56 .”
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406 · cited 2×
“The ABC-02 trial randomly assigned 410 patients with ECOG-PS ≤2 to systemic chemotherapy with gemcitabine alone or cisplatin–gemcitabine 336 ; the study showed an OS benefit in favour of cisplatin– gemcitabine (HR 0.64), a benefit confirmed in the Japanese randomized phase II BT22 study 337 .”
InfluentialSelf-citationThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · cited 1×
“CAFs are a heterogeneous population of spindle-shaped cells with mesenchymal origin that contribute to tumour progression in many human cancers 199 .”
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Research works printed but not linked: 3
- Bosman, F. T., Carneiro, F., Hruban, R. & Theise N. WHO Classification of Tumours: Digestive System Tumours 5th edn Vol. 1 (IARC, 2019).
- Hamilton, S. R. A. et al. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System 3rd edn Vol. 2 (IARC, 2000).
- Amin, M. B. et al. AJCC Cancer Staging Manual (Springer, 2017).
Cited by
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
Self-citationBiliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Self-citationFutibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206834 · Cited by 613
Self-citationCancer-associated fibroblasts in the single-cell era
Lavie, D., Ben-Shmuel, A., Erez, N., & Scherz-Shouval, R. (2022) · Nature Cancer · doi:10.1038/s43018-022-00411-z · Cited by 616
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
“158,443 Apart from primary liver cancer, PD-1 resistant NSCLC cells were characterized by a markedly lower glycolytic reserve and exhibited a signi fi cantly higher reliance on OXPHOS compared to PD-1 sensitive NSCLC cells, which implies that tumor progression leads to complex changes in lactate…”
Metadata
- Authors
- Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., Calvisi, D. F., Perugorria, M. J., Fabris, L., Boulter, L., Macias, R. I. R., Gaudio, E., Alvaro, D., Gradilone, S. A., Strazzabosco, M., Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P., Mertens, J. C., Moncsek, A., Ilyas, S. I., Heimbach, J., Koerkamp, B. G., Bruix, J., Forner, A., Bridgewater, J., Valle, J. W., & Gores, G. J.
- Affiliations
- University of the Basque Country (ES)
- Hammersmith Hospital (GB)
- Mayo Clinic (US)
- Sapienza University of Rome (IT)
- Foro Italico University of Rome (IT)
- University of Copenhagen (DK)
- University of Glasgow (GB)
- University of Regensburg (DE)
- University of Padua (IT)
- Institute of Genetics and Cancer (GB)
- University of Minnesota (US)
- Marche Polytechnic University (IT)
- Inserm (FR)
- University of Florence (IT)
- University of Milano-Bicocca (IT)
- University of Zurich (CH)
- Erasmus MC (NL)
- Instituto de Salud Carlos III (ES)
- University College London (GB)
- National Health Service (GB)
- ORCID
- Banales, Jesus M.
- Marin, Jose J. G.
- Lamarca, Angela
- Rodrigues, Pedro M.
- Khan, Shahid A.
- Roberts, Lewis R.
- Cardinale, Vincenzo
- Carpino, Guido
- Andersen, Jesper B.
- Braconi, Chiara
- Calvisi, Diego F.
- Perugorria, Maria J.
- Fabris, Luca
- Boulter, Luke
- Macias, Rocio I. R.
- Gaudio, Eugenio
- Alvaro, Domenico
- Gradilone, Sergio A.
- Strazzabosco, Mario
- Marzioni, Marco
- Coulouarn, Cédric
- Fouassier, Laura
- Raggi, Chiara
- Invernizzi, Pietro
- Mertens, Joachim C.
- Moncsek, Anja
- Ilyas, Sumera I.
- Heimbach, Julie
- Koerkamp, Bas Groot
- Bruix, Jordi
- Forner, Alejandro
- Bridgewater, John
- Valle, Juan W.
- Gores, Gregory J.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-06-30
- Volume
- 17
- Issue
- 9
- Pages
- 557-588
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC7447603
- OpenAlex
- W3039360174
- Cited by
- 2,411
- References
- 410
- Citations by year
- 2026: 259 · 2025: 482 · 2024: 461 · 2023: 434 · 2022: 455 · 2021: 271 · 2020: 39
- FWCI
- 68.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Hispana (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- Communities in ADDI (University of the Basque Country) (submittedVersion, cc-by)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Gredos (University of Salamanca) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Funders
- Cholangiocarcinoma Foundation
- Novo Nordisk Fonden (NNF19OC0058419, NNF15OC0014040)
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (K08CA236874, P50CA210964)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034989)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- cholangiocarcinoma, biliary tract cancer, tumor heterogeneity, cell of origin, genetic alterations, epigenetic modifications, molecular alterations, biomarker discovery, diagnosis, treatment, prognosis, tumor classification
- MeSH terms
- Bile Duct Neoplasms, Humans, Cholangiocarcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholangiocarcinoma 2020: the next horizon in mechanisms and management. https://app.cochat.ai/papers/10.1038/s41575-020-0310-z
- The paper
- Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., Calvisi, D. F., Perugorria, M. J., Fabris, L., Boulter, L., Macias, R. I. R., Gaudio, E., Alvaro, D., Gradilone, S. A., Strazzabosco, M., . . . Gores, G. J. (2020). Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-0310-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.